Literature DB >> 22035541

Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progression.

Newton J Hurst1, Abdo J Najy, Carolyn V Ustach, Lisa Movilla, Hyeong-Reh Choi Kim.   

Abstract

The PDGF (platelet-derived growth factor) family members are potent mitogens for cells of mesenchymal origin and serve as important regulators of cell migration, survival, apoptosis and transformation. Tumour-derived PDGF ligands are thought to function in both autocrine and paracrine manners, activating receptors on tumour and surrounding stromal cells. PDGF-C and -D are secreted as latent dimers, unlike PDGF-A and -B. Cleavage of the CUB domain from the PDGF-C and -D dimers is required for their biological activity. At present, little is known about the proteolytic processing of PDGF-C, the rate-limiting step in the regulation of PDGF-C activity. In the present study we show that the breast carcinoma cell line MCF7, engineered to overexpress PDGF-C, produces proteases capable of cleaving PDGF-C to its active form. Increased PDGF-C expression enhances cell proliferation, anchorage-independent cell growth and tumour cell motility by autocrine signalling. In addition, MCF7-produced PDGF-C induces fibroblast cell migration in a paracrine manner. Interestingly, PDGF-C enhances tumour cell invasion in the presence of fibroblasts, suggesting a role for tumour-derived PDGF-C in tumour-stromal interactions. In the present study, we identify tPA (tissue plasminogen activator) and matriptase as major proteases for processing of PDGF-C in MCF7 cells. In in vitro studies, we also show that uPA (urokinase-type plasminogen activator) is able to process PDGF-C. Furthermore, by site-directed mutagenesis, we identify the cleavage site for these proteases in PDGF-C. Lastly, we provide evidence suggesting a two-step proteolytic processing of PDGF-C involving creation of a hemidimer, followed by GFD-D (growth factor domain dimer) generation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22035541      PMCID: PMC3342761          DOI: 10.1042/BJ20111020

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  53 in total

Review 1.  Streptokinase--the drug of choice for thrombolytic therapy.

Authors:  Adinarayana Kunamneni; Thaer Taleb Abed Abdelghani; Poluri Ellaiah
Journal:  J Thromb Thrombolysis       Date:  2007-02       Impact factor: 2.300

2.  Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.

Authors:  Birgitte Vrou Offersen; Per Pfeiffer; Peter Andreasen; Jens Overgaard
Journal:  Lung Cancer       Date:  2007-01-17       Impact factor: 5.705

3.  Identification of biomarkers of human pancreatic adenocarcinomas by expression profiling and validation with gene expression analysis in endoscopic ultrasound-guided fine needle aspiration samples.

Authors:  Henrik Laurell; Michele Bouisson; Philippe Berthelemy; Philippe Rochaix; Sebastien Dejean; Philippe Besse; Christiane Susini; Lucien Pradayrol; Nicole Vaysse; Louis Buscail
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

4.  Tissue-type plasminogen activator is upregulated in metastatic breast cancer cells exposed to insulin-like growth factor-I.

Authors:  Cheryl L Chernicky; Lijuan Yi; Huiqing Tan; Judith Ilan
Journal:  Clin Breast Cancer       Date:  2005-10       Impact factor: 3.225

5.  Autocrine PDGFR signaling promotes mammary cancer metastasis.

Authors:  Martin Jechlinger; Andreas Sommer; Richard Moriggl; Peter Seither; Norbert Kraut; Paola Capodiecci; Michael Donovan; Carlos Cordon-Cardo; Hartmut Beug; Stefan Grünert
Journal:  J Clin Invest       Date:  2006-06       Impact factor: 14.808

6.  Structural requirements for activation of latent platelet-derived growth factor CC by tissue plasminogen activator.

Authors:  Linda Fredriksson; Monika Ehnman; Christina Fieber; Ulf Eriksson
Journal:  J Biol Chem       Date:  2005-05-23       Impact factor: 5.157

7.  Delineation of matriptase protein expression by enzymatic gene trapping suggests diverging roles in barrier function, hair formation, and squamous cell carcinogenesis.

Authors:  Karin List; Roman Szabo; Alfredo Molinolo; Boye Schnack Nielsen; Thomas H Bugge
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

8.  Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer.

Authors:  Sai Murali Krishna Pulukuri; Norman Estes; Jitendra Patel; Jasti S Rao
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

9.  Plasmin is the major protease responsible for processing PDGF-C in the vitreous of patients with proliferative vitreoretinopathy.

Authors:  Hetian Lei; Gisela Velez; Peter Hovland; Tatsuo Hirose; Andrius Kazlauskas
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-01       Impact factor: 4.799

10.  Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression.

Authors:  Inês Carvalho; Fernanda Milanezi; Albino Martins; Rui M Reis; Fernando Schmitt
Journal:  Breast Cancer Res       Date:  2005-08-01       Impact factor: 6.466

View more
  23 in total

1.  Differential tumorigenic potential and matriptase activation between PDGF B versus PDGF D in prostate cancer.

Authors:  Abdo J Najy; Joshua J Won; Lisa S Movilla; Hyeong-Reh C Kim
Journal:  Mol Cancer Res       Date:  2012-06-11       Impact factor: 5.852

Review 2.  PDGF/PDGFR axis in the neural systems.

Authors:  Susmita Sil; Palsamy Periyasamy; Annadurai Thangaraj; Ernest T Chivero; Shilpa Buch
Journal:  Mol Aspects Med       Date:  2018-02-06

3.  Matriptase activation and shedding through PDGF-D-mediated extracellular acidosis.

Authors:  Abdo J Najy; Gregory Dyson; Bhanu P Jena; Chen-Yong Lin; Hyeong-Reh C Kim
Journal:  Am J Physiol Cell Physiol       Date:  2015-07-08       Impact factor: 4.249

Review 4.  The wound healing, chronic fibrosis, and cancer progression triad.

Authors:  Brad Rybinski; Janusz Franco-Barraza; Edna Cukierman
Journal:  Physiol Genomics       Date:  2014-02-11       Impact factor: 3.107

Review 5.  Pharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disorders.

Authors:  Sebastian A Lewandowski; Linda Fredriksson; Daniel A Lawrence; Ulf Eriksson
Journal:  Pharmacol Ther       Date:  2016-08-12       Impact factor: 12.310

6.  An oncogenic activity of PDGF-C and its splice variant in human breast cancer.

Authors:  Alyssa Bottrell; Yong Hong Meng; Abdo J Najy; Newton Hurst; Seongho Kim; Chong Jai Kim; Eun-Sook Kim; Aree Moon; Eun Joo Kim; So Yeon Park; Hyeong-Reh Choi Kim
Journal:  Growth Factors       Date:  2019-09-23       Impact factor: 2.511

7.  Regulation of pericellular proteolysis by hepatocyte growth factor activator inhibitor type 1 (HAI-1) in trophoblast cells.

Authors:  Kazuyo Kohama; Makiko Kawaguchi; Tsuyoshi Fukushima; Chen-Yong Lin; Hiroaki Kataoka
Journal:  Hum Cell       Date:  2012-12-18       Impact factor: 4.174

8.  The factor VII-activating protease (FSAP) enhances the activity of bone morphogenetic protein-2 (BMP-2).

Authors:  Elfie Kathrin Roedel; Elisabeth Schwarz; Sandip Madhav Kanse
Journal:  J Biol Chem       Date:  2013-01-22       Impact factor: 5.157

9.  Platelet-derived growth factor-C (PDGF-C) induces anti-apoptotic effects on macrophages through Akt and Bad phosphorylation.

Authors:  Dain Son; Yi Rang Na; Eung-Soo Hwang; Seung Hyeok Seok
Journal:  J Biol Chem       Date:  2014-01-13       Impact factor: 5.157

10.  Tissue-type plasminogen activator is not necessary for platelet-derived growth factor-c activation.

Authors:  Kimberly J Riehle; Melissa M Johnson; Fredrik Johansson; Renay L Bauer; Brian J Hayes; Debra G Gilbertson; Aaron C Haran; Nelson Fausto; Jean S Campbell
Journal:  Biochim Biophys Acta       Date:  2013-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.